Search

Your search keyword '"Uy, Geoffrey L."' showing total 8 results
Start Over Author "Uy, Geoffrey L." Journal leukemia & lymphoma
8 results on '"Uy, Geoffrey L."'

1. A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Author

Assouline, Sarit, primary, Michaelis, Laura C., additional, Othus, Megan, additional, Hay, Annette E., additional, Walter, Roland B., additional, Jacoby, Meagan A., additional, Schroeder, Mark A., additional, Uy, Geoffrey L., additional, Law, Lisa Y., additional, Cheema, Faisal, additional, Sweet, Kendra L., additional, Asch, Adam S., additional, Liu, Jijun (Jane), additional, Moseley, Anna B., additional, Maher, Tracy, additional, Kingsbury, Laura L., additional, Fang, Min, additional, Radich, Jerald, additional, Little, Richard F., additional, and Erba, Harry P., additional

Published
2022
Full Text
View/download PDF

2. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Author

Assouline, Sarit, Michaelis, Laura C., Othus, Megan, Hay, Annette E., Walter, Roland B., Jacoby, Meagan A., Schroeder, Mark A., Uy, Geoffrey L., Law, Lisa Y., Cheema, Faisal, Sweet, Kendra L., Asch, Adam S., Liu, Jijun, Moseley, Anna B., Maher, Tracy, Kingsbury, Laura L., Fang, Min, Radich, Jerald, Little, Richard F., and Erba, Harry P.

Subjects
MYELODYSPLASTIC syndromes, ACUTE myeloid leukemia, CHRONIC leukemia, NIVOLUMAB, AZACITIDINE, HYPERKALEMIA
Abstract

Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Acute myeloid leukemia (AML) primarily affects older adults, for whom lower intensity therapies, such as the hypomethylating agents (HMAs) azacitidine and decitabine, or best supportive care have often been selected. In arm B, three patients had an FLT3-ITD mutation and died within 28 days of therapy initiation, one patient with FLT3-ITD mutation was randomized to the azacitidine alone arm. The study was closed prematurely after an observed excess early mortality in arm B, where six patients (24%) died within 28 days of initiating therapy versus one patient (4%) in arm A ( I p i = 0.098). [Extracted from the article]

Published
2023
Full Text
View/download PDF

3. A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes

Author

Huselton, Eric, primary, Rettig, Michael P., additional, Fletcher, Theresa, additional, Ritchey, Julie, additional, Gehrs, Leah, additional, McFarland, Kyle, additional, Christ, Stephanie, additional, Eades, William C., additional, Trinkaus, Kathryn, additional, Romee, Rizwan, additional, Kulkarni, Shashikant, additional, Ghobadi, Armin, additional, Abboud, Camille, additional, Cashen, Amanda F., additional, Stockerl-Goldstein, Keith, additional, Uy, Geoffrey L., additional, Vij, Ravi, additional, Westervelt, Peter, additional, DiPersio, John F., additional, and Schroeder, Mark A., additional

Published
2021
Full Text
View/download PDF

5. A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome

Author

Cherian, Mathew A., primary, Tibes, Raoul, additional, Gao, Feng, additional, Fletcher, Theresa, additional, Fiala, Mark, additional, Uy, Geoffrey L., additional, Westervelt, Peter, additional, Jacoby, Meagan A., additional, Cashen, Amanda F., additional, Stockerl-Goldstein, Keith, additional, DiPersio, John F., additional, and Vij, Ravi, additional

Published
2016
Full Text
View/download PDF

6. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

Author

Wartman, Lukas D., primary, Fiala, Mark A., additional, Fletcher, Theresa, additional, Hawkins, Emily R., additional, Cashen, Amanda, additional, DiPersio, John F., additional, Jacoby, Meagan A., additional, Stockerl-Goldstein, Keith E., additional, Pusic, Iskra, additional, Uy, Geoffrey L., additional, Westervelt, Peter, additional, and Vij, Ravi, additional

Published
2015
Full Text
View/download PDF

8. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.

Author

Wartman, Lukas D., Fiala, Mark A., Fletcher, Theresa, Hawkins, Emily R., Cashen, Amanda, DiPersio, John F., Jacoby, Meagan A., Stockerl-Goldstein, Keith E., Pusic, Iskra, Uy, Geoffrey L., Westervelt, Peter, and Vij, Ravi

Subjects
DRUG efficacy, LYMPHOBLASTIC leukemia treatment, MYELOID leukemia, LEUKEMIA treatment
Abstract

A letter to the editor is presented on the study regarding the effectiveness of carfilzomib drug for acute lymphoblastic leukemia (ALL) and myeloid leukemia (AML) treatment.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results